Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620919 · ClinicalTrials.gov registry record · Phase 1
Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00620919: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00620919 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00620919, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Multidetector Computed Tomography (MDCT) of the pancreas. 2. To demonstrate that RG1068-enhanced MDCT improves image quality of the pancreas in patients with chronic pancreatitis. 3. To evaluate if RG1068 enhanced MDCT results in improved delineation of structural abnormalities of the pancreatic duct as compared to non-enhanced MDCT.
Interventions
- DRUG RG1068 (Synthetic Human Secretin)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2008-02 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00620919
The ClinicalTrials.gov registry entry for NCT00620919 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RG1068 (Synthetic Human Secretin) is the first listed.
NCT00620919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00620919 about?
NCT00620919 is a clinical study titled "Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis". 1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Multidetector Computed Tomography (MDCT) of the pancreas. 2. To demonstrate that RG1068-enhanced MDCT improves image quality of the pancreas in patients with chronic p...
What is the current status of trial NCT00620919?
This trial is currently terminated. It is a Phase 1 study. The study started on 2008-02. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00620919?
The interventions under investigation include: RG1068 (Synthetic Human Secretin) (DRUG).
Who is sponsoring clinical trial NCT00620919?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.